Altimmune (ALT) Stock: Buy, Sell, or Hold?
ALT - Altimmune, Inc. Common Stock
$2.74
-0.02 (-0.91%)
▼
5d:
-10.62%
30d:
-16.62%
90d:
-11.2%
WAIT
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Nov 05, 2026
Get Alerted When ALT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: ALT is down 10.6% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: ALT is down 10.6% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: ALT is currently trading at $2.73, which is considered oversold relative to its 30-day fair value range of $2.99 to $3.34.
Technical Outlook: Technically, ALT is in a strong downtrend. The price is currently testing key support at $2.71. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: ALT scores 33/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $17.11 (+525.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ALT is in a strong downtrend. The price is currently testing key support at $2.71. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: ALT scores 33/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $17.11 (+525.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$2.99 -
$3.34
Company Quality Score
37/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
57.9%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (33/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 525.6% below Wall St target ($17.11)
- WARNING: Composite score 37/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$2.99 -
$3.34
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$2.71
Resistance Level
$3.43
Current Trend
Strong Downtrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-4.09
Wall Street Target
$17.11
(+525.6%)
Revenue Growth (YoY)
420.0%
Share & Embed Analysis
Last updated: October 03, 2026 2:35 AM ET
Data refreshes hourly during market hours. Next update: 3:35 AM
Data refreshes hourly during market hours. Next update: 3:35 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ALT showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$75 | 60 BUY |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$28 | 53 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 58 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$95 | 57 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 50 HOLD |
